首页> 外文期刊>Journal of cellular biochemistry. >LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
【24h】

LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.

机译:LRRC4通过减少SDF-1 alpha / CXCR4介导的ERK1 / 2和Akt信号通路抑制人胶质母细胞瘤细胞的增殖,侵袭和proMMP-2活化。

获取原文
获取原文并翻译 | 示例
           

摘要

Gliomas take a number of different genetic routes in the progression to glioblastoma multiforme, a highly invasive variant that is mostly unresponsive to current therapies. The alpha-chemokine stromal cell-derived factor (SDF)-1 alpha binds to the seven transmembrane G-protein-coupled CXCR-4 receptor and acts to modulate cell migration and proliferation by activating multiple signal transduction pathways. Leucine-rich repeats containing 4 (LRRC4), a putative glioma suppressive gene, inhibits glioblastoma cells tumorigenesis in vivo and cell proliferation and invasion in vitro. We also previously demonstrated that LRRC4 controlled glioblastoma cells proliferation by ERK/AKT/NF-kappa B signaling pathway. In the present study, we demonstrate that CXC chemokine receptor 4 (CXCR4) is expressed in human glioblastoma U251 cell line, and that SDF-1 alpha increases the proliferation, chemotaxis, and invasion in CXCR4+ glioblastoma U251 cells through the activation of ERK1/2 and Akt. The reintroduction of LRRC4 in U251 cells inhibits the expression of CXCR4 and SDF-1 alpha/CXCR4 axis-mediated downstream intracellular pathways such as ERK1/2 and Akt leading to proliferate, chemotactic and invasive effects. Furthermore, we provide evidence for proMMP-2 activation involvement in the SDF-1 alpha/CXCR4 axis-mediated signaling pathway. LRRC4 significantly inhibits proMMP-2 activation by SDF-1 alpha/CXCR4 axis-mediated ERK1/2 and Akt signaling pathway. Collectively, these results suggest a possible important "cross-talk" between LRRC4 and SDF-1 alpha/CXCR4 axis-mediated intracellular pathways that can link signals of cell proliferation, chemotaxis and invasion in glioblastoma, and may represent a new target for development of new therapeutic strategies in glioma.
机译:在成胶质母细胞瘤的发展过程中,胶质瘤采取了多种不同的遗传途径,这是一种高度侵入性的变体,大多数情况下对当前疗法无反应。 α趋化因子基质细胞衍生因子(SDF)-1α与七个跨膜G蛋白偶联的CXCR-4受体结合,并通过激活多种信号转导途径来调节细胞迁移和增殖。富含亮氨酸的重复序列含有4(LRRC4),这是一种推定的神经胶质瘤抑制基因,在体内抑制胶质母细胞瘤细胞的肿瘤发生,并在体外抑制细胞的增殖和侵袭。我们先前还证明了LRRC4通过ERK / AKT /NF-κB信号通路控制胶质母细胞瘤细胞增殖。在本研究中,我们证明了CXC趋化因子受体4(CXCR4)在人胶质母细胞瘤U251细胞系中表达,并且SDF-1 alpha通过激活ERK1 / 2增加CXCR4 +胶质母细胞瘤U251细胞的增殖,趋化性和侵袭性。和Akt。在U251细胞中重新引入LRRC4会抑制CXCR4和SDF-1 alpha / CXCR4轴介导的下游细胞内途径(如ERK1 / 2和Akt)的表达,从而导致增殖,趋化和侵袭作用。此外,我们提供proMMP-2激活参与SDF-1 alpha / CXCR4轴介导的信号通路的证据。 LRRC4通过SDF-1 alpha / CXCR4轴介导的ERK1 / 2和Akt信号通路显着抑制proMMP-2激活。总的来说,这些结果表明LRRC4和SDF-1 alpha / CXCR4轴介导的细胞内通路之间可能存在重要的“串扰”,这些通路可以将胶质母细胞瘤中的细胞增殖,趋化性和侵袭信号联系起来,并可能代表神经胶质母细胞瘤发展的新目标。神经胶质瘤的新治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号